Vimarsana
Biggest News Aggregation in the World

Alter Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alter Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alter Pharma Today - Breaking & Trending Today

Alter Pharma Group: Alter Pharma Acquires EcoPharmaSupply - Vimarsana News

Alter Pharma Group: Alter Pharma Acquires EcoPharmaSupply

Alter Pharma, a Belgian pharmaceutical group focused on the distribution of medicines and the development and manufacturing of generic drugs commercialized in Europe, the US (through its wholly owned

Riverside buys Belgian pharmaceuticals distributor for Alter Pharma platform - Vimarsana News

Riverside buys Belgian pharmaceuticals distributor for Alter Pharma platform

The transaction with EcoPharmaSupply represents the first add-on company for Alter Pharma since the private equity firm acquired it in 2017.

Related Topics:
Riverside CoAlter Pharma
Alter Pharma Group: Alter Pharma Acquires EcoPharmaSupply - Vimarsana News

Alter Pharma Group: Alter Pharma Acquires EcoPharmaSupply

Alter Pharma, a Belgian pharmaceutical group focused on the distribution of medicines and the development and manufacturing of generic drugs commercialized in Europe, the US (through its wholly owned

Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead - Vimarsana News

Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead Hyloris Pharmaceuticals SAAugust 4, 2021 GMT  On target to grow the broad product pipeline with at least 3 additional programmes before end 2021 Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV Expected to start 2 clinical studies and to report the results from 2 clinical studies before year-end €53.47 million in cash and cash equivalents to execute ambitious growth ...

Source: apnews.com